6.23

1.74% -0.11

Pre-market: 6.32 0.09 +1.44%

Xeris Biopharma Holdings Inc (XERS)

Overview News Price History Option Chain Financials Discussions Forecast

Xeris Biopharma Holdings Inc stock is traded at $6.23, with a volume of 1.38M. It is down -1.74% in the last 24 hours and up +3.15% over the past month. Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Previous Close:

$6.34

Open:

$6.39

24h Volume:

1.38M

Relative Volume:

0.80

Market Cap:

$1.08B

Revenue:

$291.85M

Net Income/Loss:

$554.00K

P/E Ratio:

-819.74

EPS:

-0.0076

Net Cash Flow:

$27.93M

1W Performance:

+2.30%

1M Performance:

+3.15%

6M Performance:

-36.88%

1Y Performance:

+34.27%

1-Day Range:

$6.21

$6.465

1-Week Range:

$5.97

$6.465

52-Week Range:

$4.255

$10.08

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name

Xeris Biopharma Holdings Inc

Sector

Healthcare (1106)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

844-445-5704

Address

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Employee

435

Twitter

@XerisPharma

Next Earnings Date

2026-05-07

Latest SEC Filings

XERS's Discussions on Twitter

Compare XERS vs TAK, ZTS, TEVA, HLN, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XERS Xeris Biopharma Holdings Inc	6.23	1.09B	291.85M	554.00K	27.93M	-0.0076
TAK Takeda Pharmaceutical Co Adr	16.55	52.28B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	112.54	47.33B	9.47B	2.67B	2.28B	6.0218
TEVA Teva Pharmaceutical Industries Ltd Adr	35.86	41.76B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.17	40.70B	14.54B	2.22B	2.58B	0.4871
UTHR United Therapeutics Corp	572.20	24.28B	3.18B	1.33B	1.04B	27.90

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Overweight
Aug-12-25	Resumed	H.C. Wainwright	Buy
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Mar-28-24	Initiated	Oppenheimer	Outperform
Aug-28-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Craig Hallum	Buy
Nov-17-21	Initiated	SVB Leerink	Outperform
Oct-29-21	Initiated	H.C. Wainwright	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-18-20	Initiated	Piper Sandler	Overweight
Jul-16-18	Initiated	Jefferies	Buy
Jul-16-18	Initiated	Leerink Partners	Outperform
Jul-16-18	Initiated	RBC Capital Mkts	Outperform

View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

May 02, 2026

Insider Sell Alert: Beth Hecht Sells 16,667 Shares of Xeris Biop - GuruFocus

May 02, 2026

May 01, 2026

Insider Sell Alert: Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus

May 01, 2026

Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat

May 01, 2026

Xeris Biopharma’s chief legal officer sells $103,805 in stock - Investing.com

May 01, 2026

Xeris Biopharma (XERS) officer sells 16,667 shares under 10b5-1 plan - Stock Titan

May 01, 2026

Apr 30, 2026

Xeris Biopharma (XERS) to Release Earnings on Thursday - MarketBeat

Apr 30, 2026

Apr 28, 2026

Xeris Biopharma Reports Third Quarter 2024 Financial Results - Quantisnow

Apr 28, 2026

Apr 27, 2026